Literature DB >> 18591073

Epidemiology of Parkinson's disease.

A H Rajput1, S Birdi.   

Abstract

The incidence of Parkinson syndrome in North America is 20.5/10(5), adjusted to 1970 US population, and there has been no significant change between 1935 and 1979. The composition of different Parkinson variants in the general population, however, has altered remarkably during recent decades. Arteriosclerotic Parkinsonism is very rarely diagnosed now, post-encephalitic Parkinsonism is extinct and drug induced Parkinsonism, first identified in the 1950s, is now the second most common variant in the combined community and institutionalised population survey. There has been a trend to higher incidence of Parkinson's disease in recent decades and it is predicted that the incidence would rise further if the current population survival trends continue. There is no race or gender difference for the risk of Parkinson's disease. Survival in Parkinson's disease has increased since the widespread use of levodopa. The prevalence rate of Parkinson syndrome in North America is estimated at 300/105. Increased risk of Parkinson's disease in essential tremor patients and the reported protective effect of smoking are artifactual. Twin studies show a concordance rate of 10.5% in monozygotic and 10.8% in dizygotic twins, indicating against a major genetic basis for Parkinson's disease. Several large Parkinson's disease families with autosomal dominant inheritance are well documented. In one such family, linkage to chromosome 4 is reported and mutation in the a-synuclein gene has been identified. In several other families, linkage to that region was not detected. These families are believed to inherit a Parkinson's disease susceptibility trait.

Entities:  

Year:  1997        PMID: 18591073     DOI: 10.1016/s1353-8020(97)00029-1

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  12 in total

1.  LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease.

Authors:  Carles Vilariño-Güell; Christian Wider; Owen A Ross; Barbara Jasinska-Myga; Jennifer Kachergus; Stephanie A Cobb; Alexandra I Soto-Ortolaza; Bahareh Behrouz; Michael G Heckman; Nancy N Diehl; Claudia M Testa; Zbigniew K Wszolek; Ryan J Uitti; Joseph Jankovic; Elan D Louis; Lorraine N Clark; Alex Rajput; Matthew J Farrer
Journal:  Neurogenetics       Date:  2010-04-06       Impact factor: 2.660

2.  Real life evaluation of safinamide effectiveness in Parkinson's disease.

Authors:  Francesca Mancini; Alessio Di Fonzo; Giulia Lazzeri; Linda Borellini; Vincenzo Silani; Marco Lacerenza; Cristoforo Comi
Journal:  Neurol Sci       Date:  2018-02-13       Impact factor: 3.307

Review 3.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 4.  Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.

Authors:  Peter Riederer; Thomas Müller
Journal:  J Neural Transm (Vienna)       Date:  2018-03-22       Impact factor: 3.575

Review 5.  Does mitochondrial DNA play a role in Parkinson's disease? A review of cybrid and other supportive evidence.

Authors:  Russell H Swerdlow
Journal:  Antioxid Redox Signal       Date:  2011-05-25       Impact factor: 8.401

6.  Evaluation of the visual system with visual evoked potential and optical coherence tomography in patients with idiopathic Parkinson's disease and with multiple system atrophy.

Authors:  Melike Batum; Ayşın Kısabay Ak; Mehmet Semih Arı; Hüseyin Mayali; Emin Kurt; Deniz Selçuki
Journal:  Doc Ophthalmol       Date:  2022-07-26       Impact factor: 1.854

7.  A Fuzzy Inference System for Closed-Loop Deep Brain Stimulation in Parkinson's Disease.

Authors:  Carmen Camara; Kevin Warwick; Ricardo Bruña; Tipu Aziz; Francisco del Pozo; Fernando Maestú
Journal:  J Med Syst       Date:  2015-09-18       Impact factor: 4.460

8.  Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study.

Authors:  Xia Chen; Qian Zhao; Ji Jiang; Jian Liu; Pei Hu
Journal:  Clin Drug Investig       Date:  2016-05       Impact factor: 2.859

9.  Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects.

Authors:  Wenjia Zhou; Chengzhe Lv; Quanying Zhang; Shunlin Zong; Meng Wang
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 10.  Emerging approaches in Parkinson's disease - adjunctive role of safinamide.

Authors:  Thomas Müller
Journal:  Ther Clin Risk Manag       Date:  2016-08-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.